tetrahydrogestrinone
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Nov 23, 2022 (NCT05570786)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21CC- Mol. weight
- 308.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1868702 ↗
Also known as
- a-46745
- a-46745
- dimetriose
- dimetriose
- dimetriose
- dimetrose
- ethylnorgestrienone
- ethylnorgestrienone
- gestrinone
- gestrinone
- gestrinone
- gestrinone
- gestrinone
- gestrinone
- gestrinone
- nemestran
- r-2323
- r-2323
- ru-2323
- ru-2323
- tetrahydrogestrinone
- tridomose
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06543550 | Phase 4 | Jul 30, 2024 | — |
| NCT05570786 | Phase 2 | Nov 23, 2022 | Biós Farmacêutica, Science Valley Research Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biós Farmacêutica | For profit | 1 | 0 | 1 | 2022 |
| Science Valley Research Institute | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1